Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

More than 5 million skipped getting second COVID-19 vaccine dose

By Brian Buntz | April 26, 2021

Pfizer-BioNTech vaccine

Pfizer-BioNTech vaccine image courtesy of Wikipedia

The percentage of people who failed to get the second dose of Pfizer or Moderna COVID-19 vaccines is growing, according to recent CDC data. Some five million people, or almost 8% of people who got the first vaccine dose, missed getting the second.

In mid-March, 3% of people were overdue for their second dose.

People who missed getting their second vaccine dose provided several explanations. Some wanted to avoid adverse events, which are more common after the second dose. Others believed a single dose offered sufficient protection.

Another contributing factor relates to supply constraints at vaccination sites, which are instructed not to use Moderna and Pfizer vaccines interchangeably.

The supply constraints are likely to ease the number of people making appointments for COVID-19 vaccination falls in many parts of the country.

Some states, including Arkansas and Illinois, are using phone calls, text messages and letters to persuade the partially vaccinated to get the second dose. South Carolina is amassing a supply of thousands of doses for those overdue for their second dose.

In states such as Massachusetts, compliance was higher. Some 99% of vaccine recipients had received their second dose within 42 days of receiving the first.

CDC guidelines call for people to receive the second dose within 42 days, or six weeks. Moderna recommends a 28-day gap between vaccine doses while Pfizer specifies 21 days.

Researchers don’t have a solid grasp of the degree of immunity a single vaccine dose offers. A CDC study found that people who had a single dose of vaccines from either Pfizer or Moderna had 80% protection. The duration of that immunity, however, is unclear.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Emergent Biosolutions
Emergent hid quality problems from FDA, House report concludes
World Changing Ideas
Fast Company 2022 World-Changing Ideas Awards highlight multiple pharma innovations
Pfizer logo
Pfizer ticks up on Street-beating Q1, lessens full-year guidance
Pfizer logo
Pfizer’s COVID-19 antiviral disappoints as post-exposure prophylactic 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards